Aptevo Therapeutics products

ADAPTIR-FLEX technology extends advantages of ADAPTIR technology to create protein therapeutics with varied specificity and valency and potentially new modes of action.

Demonstrated ability to produce monospecific and bispecific drug candidates; Leverages IgG1 Fc to form homodimeric bispecific molecules; IgG1-derived Fc can be mutated to ablate effector functions antibody-dependent cellcytotoxicity (ADCC) and complementdependent cytotoxicity (CDC), while maintaining original stability and half-life (confirmed by cell binding, cell function, SPRbased measurements of affinity, melting temperature) and good pharmaco-kinetic properties in preclinical studies; Binding domains are engineered from IgG variable regions, fragment libraries, receptors or ligands; Optimized to minimize proteolytic cleavage and post-translational modifications.